BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention

Reuters

03-12

BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention

March 11 (Reuters) - Gilead Sciences Inc GILD.O:

GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION
GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS
GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS
GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS
GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTS

Source text: [ID:]

Further company coverage: GILD.O

(((( Reuters.Briefs@thomsonreuters.com ;));))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2518727753"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518727753\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518727753?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-12 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518727753","market":"nz","top_or_hot":-1,"title":"BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention</title></head><body><p><span>March 11 (Reuters)</span><span> - </span>Gilead Sciences Inc <span>GILD.O</span>:</p><ul><li><p>GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION</p></li><li><p>GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS</p></li><li><p>GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS</p></li><li><p>GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS</p></li><li><p>GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC &amp; SAFETY PROFILES FOR ADOLESCENT &amp; ADULT TRIAL PARTICIPANTS</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>GILD.O</span></p><p> (((( Reuters.Briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-12 01:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention</title></head><body><p><span>March 11 (Reuters)</span><span> - </span>Gilead Sciences Inc <span>GILD.O</span>:</p><ul><li><p>GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION</p></li><li><p>GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS</p></li><li><p>GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS</p></li><li><p>GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS</p></li><li><p>GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC &amp; SAFETY PROFILES FOR ADOLESCENT &amp; ADULT TRIAL PARTICIPANTS</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>GILD.O</span></p><p> (((( Reuters.Briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZLL34.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nP8N3M007C:1","article_id":"2518727753","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518727753","pubTimestamp":1741714624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV PreventionMarch 11  - Gilead Sciences Inc GILD.O:GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTIONGILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKSGILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALSGILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTSGILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTSSource text: [ID:]Further company coverage: GILD.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4585":"ETF&股票定投概念","LU0058720904.USD":"联博国际健康护理基金A","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4139":"生物科技","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4566":"资本集团","BK4578":"CAR-T","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","GILD":"吉利德科学","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4583":"猴痘概念","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓"},"translate_title":"简介-吉利德科学公布了用于艾滋病毒预防的研究性每年一次的来那卡韦的首个临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"BRIEF-Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV PreventionMarch 11 (Reuters) - Gilead Sciences Inc GILD.O:GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTIONGILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKSGILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALSGILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTSGILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTSSource text: [ID:]Further company coverage: GILD.O (((( Reuters.Briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}